IP Library Granted Patent US 8,981,147
Granted Patent B2
US 8,981,147 · App. 14/183,827 · Granted Mar 17, 2015

Diphosphine ligand and transition metal complex using the same

Inventors: Mitsuhisa Yamano (Osaka, JP); Mitsutaka Goto (Osaka, JP); Shinji Kawaguchi (Osaka, JP); Masatoshi Yamada (Osaka, JP); Jun-ichi Kawakami (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited
C07F9/572B01J31/2452C07B53/00C07F9/5022C07F9/5027C07F9/5721C07F15/0053C07F15/0066C07F15/008C07F15/004B01J2531/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,981,147
App. No.
14/183,827
Granted
Mar 17, 2015
Kind
B2
Abstract

The present invention provides a novel ligand represented by the following formula and a novel transition metal complex having the ligand, which shows superior enantioselectivity and catalytic efficiency, particularly high catalyst activity, in various asymmetric synthesis reactions. A transition metal complex having, as a ligand, a compound represented by the formula wherein R 4 is a hydrogen atom or a C 1-6 alkyl group optionally having substituent(s), and R 5 and R 6 are each a C 1-6 alkyl group optionally having substituent(s), or the formula is a group represented by the formula wherein ring B is a 3- to 8-membered ring optionally having substituent(s).

Claims (10)

1. A compound represented by the formula

wherein:

R 4a is a C 1-6 alkyl group optionally having substituent(s), and R 5a and R 6a are each a C 1-6 alkyl group optionally having substituent(s), or

R 4a is a hydrogen atom or a C 1-6 alkyl group optionally having substituent(s), and the formula

is a group represented by the formula

wherein ring B′ is a 3- to 8-membered ring optionally having substituent(s), or a salt thereof.

2. The compound of claim 1 , wherein R 4a , R 5a and R 6a are each a C 1-6 alkyl group optionally having substituent(s).

3. The compound of claim 1 , wherein R 4a is a hydrogen atom or a C 1-6 alkyl group optionally having substituent(s), and the formula

is a group represented by the formula

wherein ring B′ is a 3- to 8-membered ring optionally having substituent(s).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 9, 2018
From: TAKEDA PHARMACEUTICAL COMPANY LIMITED
To: SPERA PHARMA, INC.
Reel/Frame 046293/0489 →
Priority Claims (1)
JP 2005-272599 · Sep 20, 2005 · national
Continuity (2)
Division 11992167
Related Publication 20140171655A1 · Jun 19, 2014